#

: 14
A Rothschild analyst deemed the markets reaction to the results of Modernas skin cancer vaccine trials to be excessive / Photo: Shutterstock.com / Panaceum Media
News·
An analyst called Moderna's stock overvalued after it rose 400% since the start of the year
BioNTech and Roche have halted trials of an experimental personalized mRNA immunotherapy for patients with stage II–III colorectal cancer / Photo: Kittyfly / Shutterstock.com
News·
BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?
Moderna will use the proceeds to fund the development of a cancer drug and to pay off debt / Photo: Shutterstock.com / Dmitriy Melnikov
News·
Moderna to Raise $2 Billion Following a Surge in Its Stock Price — Including Funding for a Cancer Vaccine
It will not be possible to automatically extend the use of a personalized vaccine against melanoma recurrence to other types of cancer / Photo: Poetra.RH / Shutterstock.com
News·
Not a Panacea: What Might Investors Have Overlooked in the News About the “Cancer Vaccine”?
Modernas 177% stock surge led to multibillion-dollar paper losses for short sellers / Photo: Shutterstock.com / Tada Images
News·
Moderna's stock price nearly tripled, resulting in $5.5 billion in paper losses for short sellers
Photo: Taljat David / Shutterstock.com
News·
Moderna announced the success of its experimental cancer vaccine. Its stock soared 120%.
Shares of vaccine manufacturer Moderna hit their highest level since September 2024 / Photo: Panaceum Media / Shutterstock.com
News·
Moderna shares hit a two-year high after a 13% surge. It's all about a new treatment
Moderna has collaborated with a South Korean university researching hantavirus since 2024: the vaccine has reached trials on mice / Photo: Golden Shrimp/ Shutterstock.com
News·
Moderna's stock soared 6%. The company is developing a vaccine against hantavirus
Moderna shares rose after the regulator approved the mRNA vaccine application/Photo: Shutterstock.com/Inna Dodor
News·
A regulator in the US has had a dramatic change of heart on the new Moderna vaccine. Its shares rose 6%
US regulators have denied Modernas application for approval of a new flu vaccine / Photo: Shutterstock.com/Golden Shrimp
News·
Moderna's stock fell due to regulatory concerns. A more important development is also under attack
Morning in New York: focus on reports in the absence of macro drivers
News·
Morning in New York: focus on reports in the absence of macro drivers
Morning in New York: buyers set for revenge
News·
Morning in New York: buyers set for revenge
Load more